Otonomy to Present at Piper Jaffray Healthcare Conference

SAN DIEGO, Nov. 22, 2017 -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear, today announced that David A. Weber, Ph.D., president and chief executive officer, will present at the 29^th Annual Piper Jaffray Healthcare Conference on Wednesday, November 29, 2017 at 12:30 p.m. EST (9:30 a.m. PST) at the Lotte New York Palace in New York City.

A live audio webcast of the presentation will be available through the Events and Presentations page of the company's website (www.otonomy.com).  

About Otonomy

Otonomy is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and disorders of the ear. OTIPRIO^® (ciprofloxacin otic suspension) is approved in the United States for use during tympanostomy tube placement surgery in pediatric patients, an sNDA has been accepted for filing by the FDA for acute otitis externa (AOE) and a successful End-of-Phase 2 review has been completed with the FDA for acute otitis media with tympanostomy tubes (AOMT). OTIVIDEX™ is a steroid in development for the treatment of Ménière’s disease. OTO-311 is an NMDA receptor antagonist for the treatment of tinnitus that has completed a Phase 1 clinical safety trial. Multiple programs targeting sensorineural hearing loss including age-related hearing loss are in preclinical development. These programs involve the anatomical and functional restoration of ribbon synapses, protection of hair cells from chemotoxicity, and regeneration of hair cells. For additional information please visit www.otonomy.com.

Contacts:
Investor Inquiries
Westwicke Partners
Robert H. Uhl
Managing Director
858.356.5932
[email protected]